Novel ethylenediamine derivatives

Details Novel ethylenediamine derivatives Novel ethylenediamine derivatives

C - Chemistry, Metallurgy

07

D

C07D 237/20 (2006.01) A61K 31/437 (2006.01) A61K 31/4439 (2006.01) A61K 31/444 (2006.01) A61K 31/4545 (2006.01) A61K 31/496 (2006.01) A61K 31/50 (2006.01) A61K 31/5377 (2006.01) A61K 31/541 (2006.01) A61K 31/55 (2006.01) A61P 7/02 (2006.01) A61P 9/00 (2006.01) A61P 9/04 (2006.01) A61P 9/10 (2006.01) A61P 43/00 (2006.01) C07D 213/75 (2006.01) C07D 401/04 (2006.01) C07D 401/14 (2006.01) C07D 413/12 (2006.01) C07D 471/04 (2006.01) C07D 513/04 (2006.01)

Patent

CA 2511500

A compound represented by the following general formula (1): Q1-Q2-T0-N(R1)-Q3- N(R2)-T1-Q4 (1) wherein R1 and R2 represent each hydrogen, etc.; Q1 represents optionally substituted and saturated or unsaturated 5- to 6-membered cyclic hydrocarbyl, etc.; Q2 represents a single bond, etc.; Q3 represents a group - C(R3a)(R4a)-{C(R3b)(R4b)}m1-{C(R3c)(R4c)}m2-{C(R3d)(R4d)}m3-{C(R3e)(R4e)}m4- C(R3f)(R4f)- (wherein R3a to R4e represent each hydrogen, etc.); T0 represents carbonyl, etc.; and T1 represents -COCONR-, etc.; its salt, solvates thereof or N-oxides of the same. These compounds are useful as preventives and/or remedies for cerebral infarction, cerebral embolism, myocardial infarction, angina, pulmonary infarction, pulmonary embolism, Burger~s disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombosis after artificial valve/joint replacement, thrombosis and reocclusion after reconstructing blood circulation, systemic inflammatory response syndrome (SIRS), multiorgan dysfunction syndrome (MODS), thrombosis in extracorporeal circulation and blood coagulation in blood collection.

L'invention concerne un composé représenté par la formule générale (I), dans laquelle R?1¿ et R?2¿ représentent chacun hydrogène, etc., Q?1¿ représente hydrocarbyle cyclique à 5 ou 6 éléments saturé ou insaturé éventuellement substitué, etc., Q?2¿ représente une liaison simple, etc., Q?3¿ représente un groupe C(R?3a¿)(R?4a¿)-{C(R?3b¿)(R?4b¿)}m?1¿-{C(R?3c¿)(R?4c¿)}m?2¿-{C(R?3d¿)(R?4d¿)}m?3¿-{C(R?3e¿)(R?4e¿)}m?4¿-C(R?3f¿)(R?4f¿)- (où R?3a¿ à R?4e¿ représentent chacun hydrogène, etc.), T?0¿ représente carbonyle, etc., et T?1¿ représente COCONR-, etc. L'invention concerne également un sel, des solvates ou des N-oxydes dudit composé. Ces composés sont utiles comme agents prophylactiques et/ou thérapeutiques pour l'infarctus cérébral, l'embolie cérébrale, l'infarctus du myocarde, l'angine, l'infarctus pulmonaire, l'embolie pulmonaire, la maladie de Burger, la thrombose veineuse profonde, le syndrome de coagulation intravasculaire disséminée, la thrombose après remplacement d'articulation/valvule artificielle, la thrombose et la réocclusion après reconstruction de la circulation sanguine, le syndrome de réponse inflammatoire systémique (SIRS), le syndrome de dysfonction multiorganique (MODS), la thrombose dans la circulation extra-corporelle et la coagulation sanguine dans le prélèvement sanguin.

Affiliated with

Also associated with

Rating

Novel ethylenediamine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Novel ethylenediamine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel ethylenediamine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1938249